

Improvement of primary health care for patients with diabetes

Submission date 10/03/2011	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 17/06/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 15/05/2023	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

The aim of this study is to improve primary healthcare for patients with poorly regulated type 2 diabetes mellitus by improving communication between the patient and the general practitioner (GP). We want to enable participating GPs to identify the needs of patients suffering from poorly regulated type 2 diabetes mellitus, and to foster shared decision-making.

Who can participate?

We will recruit about 60 GPs in three study centres (Rostock, Düsseldorf and Witten-Herdecke), who will each include about 13 randomly chosen type 2 diabetes mellitus patients (780 in total).

What does the study involve?

Participating GPs will be randomly allocated into either the intervention or the control group. Patient data, such as HbA1c level and prescribed drugs, will be collected at five different points in time during the study period of 36 months. Patients whose GPs are assigned into the control group will be treated as usual. The GPs assigned to the intervention group will have a conversation with a GP peer, which aims at increasing their motivation to improve poorly regulated blood sugar levels of patients suffering from type 2 diabetes. They will also be trained and equipped with a computer-based communication tool called arriba, which is especially adapted to patients suffering from diabetes. The effect of the intervention will be measured by the changes in the patient's blood sugar level, by their level of participation in the process of shared decision-making, and their quality of life.

What are the possible benefits and risks of participating?

Patients may benefit from improved management of their type 2 diabetes. There are no risks of participating.

Where is the study run from?

We will recruit about 60 GPs in three study centres (Rostock, Düsseldorf and Witten-Herdecke). The study is run from the University of Rostock (Germany).

When is the study starting and how long is it expected to run for?

The study started in March 2011 and will run until August 2015.

Who is funding the study?
German Federal Ministry of Education and Research (BMBF) (Germany).

Who is the main contact?
Prof Attila Altiner
ifa.sekretariat@med.uni-rostock.de

Contact information

Type(s)
Scientific

Contact name
Prof Attila Altiner

Contact details
University of Rostock
Medizinische Fakultät
Institut für Allgemeinmedizin
POB 100888
Rostock
Germany
18055
+49 (0)38 1494 2481
ifa.sekretariat@med.uni-rostock.de

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
01GX1041

Study information

Scientific Title
Improvement of primary health care of patients with poorly regulated diabetes mellitus type 2 using shared decision-making

Acronym
DEBATE

Study objectives
Changing the communication behaviour of general practitioners to foster shared decision-making (with their patients) utilising developed top decision-aid-diabetes (decision-aid arriba-

diabetes) improves health outcomes of patients with poorly regulated diabetes cared for in primary health. HbA1c serves as primary outcome measure.

On 19/05/2014 the overall trial end date was changed from 28/02/2014 to 31/08/2015.

On 30/06/2015 the target number of participants was changed from '60 GPs each with 13 patients; a total of 780 patients' to '108 GPs, each recruiting a consecutive sample of up to 13 patients (on average 7.8 patients per practice), a total of 843 patients'.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Committee of the Medical Faculty, University of Rostock, 25/05/2011

Study design

Cluster-randomised controlled trial with educative intervention

Primary study design

Interventional

Secondary study design

Cluster randomised trial

Study setting(s)

GP practice

Study type(s)

Treatment

Participant information sheet

http://allgemeinmedizin.med.uni-rostock.de/uploads/media/Informationsblatt-Pat_DEBATE_20110415.pdf (In German)

Health condition(s) or problem(s) studied

Diabetes mellitus type 2

Interventions

1. Cluster-randomised multi-centre controlled trial with an educative intervention (peer-visit and decision-aid arriba-diabetes)
2. Clusters are composed by GPs and patients
3. The GPs in the intervention group will receive an educational peer-visit
4. The peer himself will be a specially trained GP
5. The control group will receive care as usual
6. The study will be performed under real practice conditions

Intervention Type

Behavioural

Primary outcome measure

Current primary outcome as of 10/01/2012

1. Change of HbA1c at 6, 12, 18, 24 months compared to HbA1c at baseline
2. HbA1c will be measured as routine examination, as the case may be within the scope of the German Disease Management Program performed at GP's medical practice

Previous primary outcome

1. Change of HbA1c at 6, 12, 18, 24 months compared to HbA1c at baseline
2. HbA1c will be measured as routine examination within the scope of the German Disease Management Program performed at GP's medical practice

Secondary outcome measures

Current secondary outcome as of 10/01/2012

1. Patient's evaluation of patient-centeredness and life quality (PACIC-D, PEF-FB-9, BÄK-questionnaire, EQ-5D, PAID)
2. Cardiovascular risk prognosis
3. Pharmacotherapy

Previous secondary outcome

1. Patient's evaluation of patient-centeredness and life quality (PACIC-D, PEF-FB-9, SF-36)
2. Cardiovascular risk prognosis
3. Pharmacotherapy

Overall study start date

01/03/2011

Completion date

31/08/2015

Eligibility

Key inclusion criteria

Current inclusion criteria as of 30/06/2015:

Patients:

1. Diabetes mellitus type 2
2. HbA1c level of 8.0 or above at the time of recruitment
3. Ability to informed consent
4. Fluency in the German language

GPs:

1. General practitioner or internist, working as GP or practitioner with KV admission (Association of Statutory Health Insurance Physicians)

Previous inclusion criteria from 10/01/2012 to 30/06/2015:

Patients:

1. Diabetes mellitus type 2
2. HbA1c level of 8.1 or above at the time of recruitment
3. Ability to informed consent
4. Fluency in the German language

GPs:

1. General practitioner or internist, working as GP or practitioner with KV admission (Association of Statutory Health Insurance Physicians)

Original inclusion criteria until 10/01/2012:**Patients:**

1. Diabetes mellitus type 2
2. HbA1c level of 8.5 or above at the time of recruitment
3. Ability to informed consent
4. Fluency in the German language

GPs:

1. General practitioner or internist, working as GP or practitioner with KV admission (Association of Statutory Health Insurance Physicians)
2. Participation on the Disease Management Program diabetes mellitus type 2

Participant type(s)

Mixed

Age group

Adult

Sex

Both

Target number of participants

108 GPs, each recruiting a consecutive sample of up to 13 patients (on average 7.8 patients per practice), a total of 843 patients

Total final enrolment

833

Key exclusion criteria

1. Severe comorbidity
2. Life expectancy of less than 18 months

Date of first enrolment

01/03/2011

Date of final enrolment

31/08/2015

Locations**Countries of recruitment**

Germany

Study participating centre

The Institute of General Practice
University Medical Center Rostock
Doberaner Strasse 142
P.O. Box 108880
Rostock
Germany
18057

Study participating centre

The Institute of General Practice
Universitätsklinikum der Heinrich-Heine Universität Düsseldorf
Moorenstraße 5
Düsseldorf
Germany
40225

Study participating centre

The Institute of General Practice and Family Practice
Fakultät für Gesundheit
Universität Witten/Herdecke
Alfred-Herrhausen-Straße 50
Witten
Germany
58448

Sponsor information

Organisation

German Federal Ministry of Education and Research (BMBF) (Germany)

Sponsor details

c/o Projektträger im DLR
Heinrich-Konen-Straße 1
Bonn
Germany
53227
+49 (0)22 8382 1152
Eva.Becher@dlr.de

Sponsor type

Government

Website

<http://dlr.de>

ROR

<https://ror.org/04pz7b180>

Funder(s)

Funder type

Government

Funder Name

Bundesministerium für Bildung und Forschung

Alternative Name(s)

Federal Ministry of Education and Research, BMBF

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Germany

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	25/06/2019	27/06/2019	Yes	No
Results article		15/05/2021	17/05/2021	Yes	No
Results article	Secondary analysis	13/05/2023	15/05/2023	Yes	No